Data Provided by Refinitiv. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Rocket is at an exciting stage of growth, with a rich pipeline of development-stage opportunities and the potential to transform the lives of patients afflicted with rare disease. The Empire State Building 350 Fifth Avenue Suite 7530 New York, NY 10118.

"Notably this quarter, we completed patient treatment in the low dose cohort for RP-A501 in the Phase 1 Danon Disease trial with no dose-limiting toxicities, and are now pleased to report FDA and IDSMC clearance to advance to a higher dose cohort.

“We now have four gene therapy programs in the clinic, have established proof of concept for our lenti pipeline utilizing our commercial-grade ‘Process B’ manufacturing in both FA and LAD-I and have treated the first three patients in our Phase 1 trial for Danon Disease.” 646.440.9100; patients@rocketpharma.com; info@rocketpharma.com In the coming months, we look forward to presenting updated FA ‘Process A’ and LAD-I ‘Process B’ data at ASGCT, treating our first patient in a higher dose cohort for RP-A501, and bringing our fifth program, IMO, to the clinic."Dr. © Rocket Pharmaceuticals, Ltd. All rights reserved. "Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket") is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare disorders. We also continued to progress our clinical programs for FA, LAD-I, and PKD. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.

Rocket’s Research & Development (R&D) and Chemistry, Manufacturing and Controls (CMC) operations will be housed in a new … Shah continued, "With regard to the COVID-19 pandemic, we are well-positioned overall to continue our progress while we monitor and adjust to this challenging global crisis. Nonetheless, we remain on track for providing updates on our lentiviral pipeline. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Quicken Loans and Rocket Mortgage Parent Quintuple Net Revenue in Q2Sarina Wiegman to replace Phil Neville as England Women boss next yearEngland Women announce Wiegman as Neville's replacementRocket Companies Jumps After Pre-Announcing 437% Revenue GrowthDutch boss Wiegmann to replace Neville as England coachAmazon taking over empty J.C. Penney and Sears stores means the end of the mall: former retail CEONo evidence of 'any significant fraud within our mail-in voting system': Pres. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases.

“2019 was a pivotal year for Rocket marked by multiple clinical and regulatory achievements across the pipeline,” said Gaurav Shah, M.D., Chief Executive Officer and President of Rocket. Accordingly, you should not place undue reliance on these forward-looking statements. Rocket Pharmaceuticals Inc., an emerging gene therapy organization, is seeking a top tier candidate for a Plant Controller position. "Notably this quarter, we completed patient treatment in the low dose cohort for RP-A501 in the Phase 1 Danon Disease trial with no dose-limiting toxicities, and are now pleased to report FDA and IDSMC clearance to advance to a higher dose cohort. Best Cities for Jobs 2020 NEW!